|
Infection management and ASP
|
|
ASP available in the ICU
|
499 (63%)
|
|
Any restriction of antimicrobials
|
478 (62%)
|
|
Availability of local treatment guidelines
|
619 (82%)
|
|
Quantitative monitoring of antimicrobial use
|
409 (56%)
|
|
Availability of cumulative antimicrobial susceptibility reports
|
506 (70%)
|
|
Use of therapeutic drug monitoring (TDM)
|
435 (61%)
|
|
Use of prolonged/continuous infusion of antimicrobials
|
539 (76%)
|
|
Implementation of restriction of antimicrobials
|
|
Antibiotic order forms
|
198 (41%)
|
|
Pre-authorization
|
156 (33%)
|
|
Post-authorization
|
125 (26%)
|
|
Post-prescription review
|
130 (27%)
|
|
Telephone feedback
|
114 (24%)
|
|
Formulary restriction
|
89 (19%)
|
|
Mandatory bedside consultation
|
91 (19%)
|
|
Computerized alerts
|
56 (12%)
|
|
Automatic stop orders
|
43 (9%)
|
|
Availability of guidelines/standards
|
|
De-escalation of therapy
|
410 (50%)
|
|
Duration of therapy
|
377 (46%)
|
|
Dose optimization
|
357 (44%)
|
|
Discontinuation
|
266 (33%)
|
|
Antimicrobials with available TDM
|
|
Glycopeptides
|
387 (89%)
|
|
Aminoglycosides
|
333 (77%)
|
|
Carbapenems
|
138 (32%)
|
|
Penicillins
|
131 (30%)
|
|
Azole antifungals
|
117 (27%)
|
|
Cephalosporins
|
76 (17%)
|
|
Linezolid
|
68 (16%)
|
|
Echinocandin antifungals
|
66 (15%)
|
|
Colistin
|
52 (12%)
|
|
Quinolones
|
44 (10%)
|
|
Daptomycin
|
36 (8%)
|
|
Antimicrobials with prolonged/continuous infusion
|
|
Penicillins
|
410 (76%)
|
|
Carbapenems
|
405 (75%)
|
|
Glycopeptides
|
269 (50%)
|
|
Cephalosporins
|
163 (30%)
|
|
Linezolid
|
71 (13%)
|
|
Azole antifungals
|
39 (7%)
|
